Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Amino Acids

• Publication date

  2011-12-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00726-011-1184-8PMID 22139413PMCID PMC3883350
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice.

  2011cited by this paper
• The absence of VPAC2 leads to aberrant antibody production in Aspergillus fumigatus sensitized and challenged mice.

  2011cited by this paper
• Pituitary adenylate cyclase‐activating peptide receptor 1 mediates anti‐inflammatory effects in allergic airway inflammation in mice

  2011cited by this paper
• The potential role of Th17 in mediating the transition from acute to chronic autoimmune inflammation: rheumatoid arthritis as a model.

  2011cited by this paper
• Inhalable powder formulation of vasoactive intestinal peptide derivatives, [R^ , L^ ]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats

  2011cited by this paper
• VIP blockade leads to microcephaly in mice via disruption of Mcph1-Chk1 signaling.

  2011cited by this paper
• VIP-induced neuroprotection of the developing brain.

  2011cited by this paper
• Absence of Vasoactive Intestinal Peptide Expression in Hematopoietic Cells Enhances Th1 Polarization and Antiviral Immunity in Mice

  2011cited by this paper
• Foxp3+ regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin.

  2011cited by this paper
• VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies

  2011cited by this paper
• New insights into the role of VIP on the ratio of T‐cell subsets during the development of autoimmune diabetes

  2010cited by this paper
• Neuropeptide receptors in intestinal disease: physiology and therapeutic potential.

  2010cited by this paper
• VIP and PACAP.

  2010cited by this paper
• FOXP3+ regulatory T cells in the human immune system

  2010cited by this paper
• Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.

  2010cited by this paper
• Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs.

  2010cited by this paper
• Vasoactive Intestinal Peptide Induces Cell Cycle Arrest and Regulatory Functions in Human T Cells at Multiple Levels

  2010cited by this paper
• How tolerogenic dendritic cells induce regulatory T cells.

  2010cited by this paper
• Vasoactive intestinal peptide loss leads to impaired CNS parenchymal T-cell infiltration and resistance to experimental autoimmune encephalomyelitis

  2010cited by this paper
• Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.

  2010cited by this paper
• Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis.

  2010cited by this paper
• Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.

  2010cited by this paper
• Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases

  2010cited by this paper
• Vasoactive Intestinal Peptide (VIP) Treatment of Parkinsonian Rats Increases Thalamic Gamma-Aminobutyric Acid (GABA) Levels and Alters the Release of Nerve Growth Factor (NGF) by Mast Cells

  2010cited by this paper
• Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease

  2010cited by this paper
• Protective Effect of Intravitreal Injection of Vasoactive Intestinal Peptide–Loaded Liposomes on Experimental Autoimmune Uveoretinitis

  2009cited by this paper
• VPAC and PAC receptors: From ligands to function.

  2009cited by this paper
• Pituitary Adenylate Cyclase-Activating Polypeptide and Its Receptors: 20 Years after the Discovery

  2009cited by this paper
• Vasoactive intestinal peptide attenuates concanavalin A-mediated liver injury.

  2009cited by this paper
• VIP modulates the pro‐inflammatory maternal response, inducing tolerance to trophoblast cells

  2009cited by this paper
• Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease

  2009cited by this paper
• Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages

  2009cited by this paper
• Neuropeptides kill African trypanosomes by targeting intracellular compartments and inducing autophagic-like cell death

  2009cited by this paper
• Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis

  2009cited by this paper
• Induction of Alloantigen-Specific Human T Regulatory Cells by Vasoactive Intestinal Peptide1

  2009cited by this paper
• Cutting Edge: Vasoactive Intestinal Peptide (VIP) Induces Differentiation of Th17 Cells with a Distinctive Cytokine Profile1

  2008cited by this paper
• Inhalation of vasoactive intestinal peptide in pulmonary hypertension

  2008cited by this paper
• Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.

  2008cited by this paper
• In vivo delivery of lentiviral vectors expressing vasoactive intestinal peptide complementary DNA as gene therapy for collagen-induced arthritis.

  2008cited by this paper
• Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites.

  2008cited by this paper
• Vasoactive intestinal peptide protects against β‐amyloid‐induced neurodegeneration by inhibiting microglia activation at multiple levels

  2008cited by this paper
• Neuropeptides rescue mice from lethal sepsis by down-regulating secretion of the late-acting inflammatory mediator high mobility group box 1.

  2008cited by this paper
• Genetic association of vasoactive intestinal peptide receptor with rheumatoid arthritis: altered expression and signal in immune cells.

  2008cited by this paper
• A functional polymorphism of the vasoactive intestinal peptide receptor 1 gene correlates with the presence of HLA-B *2705 in Sardinia

  2008cited by this paper
• VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4.

  2008cited by this paper
• The Therapeutic Effect of Vasoactive Intestinal Peptide on Experimental Arthritis is Associated with CD4+CD25+ T Regulatory Cells

  2008cited by this paper
• Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation

  2007cited by this paper
• Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy

  2007cited by this paper
• Vasoactive intestinal peptide and the mammalian circadian system.

  2007cited by this paper
• Role of VIP and PACAP in islet function.

  2007cited by this paper
• Role of PACAP and VIP in astroglial functions.

  2007cited by this paper
• Involvement of VIP and PACAP in neonatal brain lesions generated by a combined excitotoxic/inflammatory challenge.

  2007cited by this paper
• Pivotal Advance: Vasoactive intestinal peptide inhibits up‐regulation of human monocyte TLR2 and TLR4 by LPS and differentiation of monocytes to macrophages

  2007cited by this paper
• From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP

  2007cited by this paper
• Molecular mechanisms involved in vasoactive intestinal peptide receptor activation and regulation: current knowledge, similarities to and differences from the A family of G-protein-coupled receptors.

  2007cited by this paper
• Vasoactive intestinal peptide in neurodevelopmental disorders: therapeutic potential.

  2007cited by this paper
• A novel VIP signaling pathway in T cells cAMP-->protein tyrosine phosphatase (SHP-2?)-->JAK2/STAT4-->Th1 differentiation.

  2007cited by this paper
• Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders?

  2007cited by this paper
• Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP.

  2006cited by this paper
• Vasoactive intestinal peptide induces regulatory dendritic cells that prevent acute graft-versus-host disease while maintaining the graft-versus-tumor response.

  2006cited by this paper
• VIP Prevents Experimental Multiple Sclerosis by Downregulating Both Inflammatory and Autoimmune Components of the Disease

  2006cited by this paper
• A Novel Mechanism for Immunosuppression: from Neuropeptides to Regulatory T Cells

  2006cited by this paper
• Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells.

  2006cited by this paper
• Clues to VIP Function from Knockout Mice

  2006cited by this paper
• Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide.

  2006influential reference
• VIP down-regulates TLR4 expression and TLR4-mediated chemokine production in human rheumatoid synovial fibroblasts.

  2006cited by this paper
• Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.

  2006cited by this paper
• Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.

  2006cited by this paper
• Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis.

  2006cited by this paper
• The Neuropeptide Vasoactive Intestinal Peptide Generates Tolerogenic Dendritic Cells1

  2005cited by this paper
• Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjögren’s syndrome

  2005cited by this paper
• VIP Attenuation of the Severity of Experimental Pancreatitis Is Due to VPAC1 Receptor-Mediated Inhibition of Cytokine Production

  2005cited by this paper
• Granzyme B, a New Player in Activation-Induced Cell Death, Is Down-Regulated by Vasoactive Intestinal Peptide in Th2 but Not Th1 Effectors1

  2005cited by this paper
• cDNA Array Analysis of Cytokines, Chemokines, and Receptors Involved in the Development of TNBS‐Induced Colitis: Homeostatic Role of VIP

  2005cited by this paper
• Time‐course expression of Toll‐like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP

  2005cited by this paper
• Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders.

  2005cited by this paper
• VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells

  2004cited by this paper
• VIP/PACAP oppositely affects immature and mature dendritic cell expression of CD80/CD86 and the stimulatory activity for CD4+ T cells

  2004cited by this paper
• The Significance of Vasoactive Intestinal Peptide in Immunomodulation

  2004influential reference
• Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.

  2004cited by this paper
• Bone and brain: a review of neural, hormonal, and musculoskeletal connections.

  2004cited by this paper
• c-Maf and JunB Mediation of Th2 Differentiation Induced by the Type 2 G Protein-Coupled Receptor (VPAC2) for Vasoactive Intestinal Peptide1

  2004cited by this paper
• The roles of vasoactive intestinal polypeptide in the mammalian circadian clock.

  2003cited by this paper
• Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

  2003cited by this paper
• Vasoactive intestinal peptide inhibits IL-8 production in human monocytes.

  2003influential reference
• Roles of Vasoactive Intestinal Peptide (VIP) in the Expression of Different Immune Phenotypes by Wild-Type Mice and T Cell-Targeted Type II VIP Receptor Transgenic Mice1

  2003cited by this paper
• INHIBITION OF ENDOTOXIN-INDUCED MACROPHAGE CHEMOKINE PRODUCTION BY VASOACTIVE INTESTINAL PEPTIDE AND PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE IN VITRO AND IN VIVO

  2003influential reference
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: players in innate and adaptive immunity.

  2003cited by this paper
• Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation

  2003influential reference
• Increased expression of interleukin 17 in inflammatory bowel disease

  2003cited by this paper
• VIPase autoantibodies in Fas‐defective mice and patients with autoimmune disease

  2003cited by this paper
• Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma

  2003influential reference
• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension.

  2003cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase‐activating polypeptide inhibit chemokine production in activated microglia

  2002cited by this paper
• Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor

  2002cited by this paper
• Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the MEKK1/MEK4/JNK signaling pathway in endotoxin-activated microglia.

  2002cited by this paper
• VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells.

  2002cited by this paper
• Cutting Edge: Is Vasoactive Intestinal Peptide a Type 2 Cytokine?

  2001influential reference
• Vasoactive intestinal peptide: cardiovascular effects.

  2001cited by this paper

• Comparative Evaluation of Deoxyribonucleic Acid Methylation Patterns of Neuropeptides in Chronic Periodontitis Cases with and without Chronic Stress: A Case–Control Study

  2026cites this paper
• Brain peptides in Alzheimer’s disease - pathophysiology and therapeutic advances

  2026cites this paper
• Neuroimmune Crosstalk in Psoriasis: Mechanisms and Therapeutic Implications

  2025cites this paper
• Myopia Pathogenesis and Vasoactive Intestinal Peptide: Molecular Mechanisms, Experimental Models, and Clinical Implications.

  2025cites this paper
• The Involvement of the Peptidergic Systems in Breast Cancer Development

  2025cites this paper
• Lung Ischemia–Reperfusion Injury in Lung Transplant Surgery: Where Do We Stand?

  2025cites this paper
• The brain-joint axis: links between osteoarthritis and neurodegenerative disorders in aging.

  2025cites this paper
• Hormonal Alterations in Individuals with Obesity After Metabolic Bariatric Surgery: A Narrative Review

  2025cites this paper
• VIPR1 induces cuproptosis and inhibits the HIF‐1α pathway in colon cancer

  2025cites this paper
• The Expanding Role of ILC2s in Allergic Airways Disease

  2025cites this paper
• Inhaled Aviptadil for Post-COVID Lung Injury: Early Promise, Future Directions

  2025cites this paper
• Targeting the VIP-VPAC Pathway in Melanoma Models Inhibits Tumor Growth and Liver Metastasis.

  2025cites this paper
• Overexpression of colonic VIP ameliorates cognitive function and barrier system damage caused by sevoflurane anesthesia and surgery in aged rats with fragile brain functions.

  2025cites this paper
• Neurotransmitter and neuropeptide regulation of gut immunity.

  2025cites this paper
• Deciphering distinct genetic risk factors for FTLD-TDP pathological subtypes via whole-genome sequencing

  2025cites this paper
• ADCYAP1 as a pan-solid cancer biomarker: predictor of immunotherapy efficacy in bladder cancer and prognostic potential across solid tumors

  2025cites this paper
• Understanding the functional significance of the labia minora: a scoping review on sexual physiology.

  2025cites this paper
• Ovarian premature aging: VIP as key regulator of fibro-inflammation and foamy macrophages generation.

  2025cites this paper
• Autonomic nervous system imbalance in diabetic mouse choroids.

  2025cites this paper
• Neuropeptides and the Autonomic Nervous System in Prader–Willi Syndrome

  2025cites this paper
• Microglia cells treated with synthetic vasoactive intestinal peptide or transduced with LentiVIP protect neuronal cells against degeneration

  2024cites this paper
• A scoring model based on bacterial lipopolysaccharide-related genes to predict prognosis in NSCLC

  2024cites this paper
• Neuropeptides or their receptors in pathogenesis of lung diseases and therapeutic potentials.

  2024cites this paper
• In silico and pharmacological evaluation of GPR65 as a cancer immunotherapy target regulating T-cell functions

  2024cites this paper
• Vasoactive intestinal peptide promotes secretory differentiation and mitigates radiation-induced intestinal injury

  2024cites this paper
• Increased Expression of the Neuropeptides PACAP/VIP in the Brain of Mice with CNS Targeted Production of IL-6 Is Mediated in Part by Trans-Signalling

  2024cites this paper
• Potential applications of mesenchymal stem cells in ocular surface immune-mediated disorders.

  2024cites this paper
• Emerging pharmacological targets for alcohol use disorder.

  2024cites this paper
• Loss of Function of Vasoactive-intestinal Peptide Alters Sex Ratio and Reduces Male Reproductive Fitness in Zebrafish

  2024cites this paper
• Paraneoplastic syndromes in childhood neuroblastoma

  2024cites this paper
• A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Bioactive Peptides.

  2024cites this paper
• Bridging the Mind and Gut: Uncovering the Intricacies of Neurotransmitters, Neuropeptides, and their Influence on Neuropsychiatric Disorders.

  2024cites this paper
• Research on the mechanism of prednisone in the treatment of ITP via VIP/PACAP-mediated intestinal immune dysfunction

  2023cites this paper
• Crosstalk of nervous and immune systems in pancreatic cancer

  2023cites this paper
• Immunomodulatory role of vasoactive intestinal peptide and ghrelin in Oncorhynchus mykiss

  2023influential citation
• Insights into the molecular mechanisms and signalling pathways of epithelial to mesenchymal transition (EMT) in colorectal cancer: A systematic review and bioinformatic analysis of gene expression.

  2023cites this paper
• Podophyllotoxin-mediated neurotoxicity via the microbiota-gut-brain axis in SD rats based on the toxicological evidence chain (TEC) concept.

  2023cites this paper
• Capillary electrophoresis in the analysis of therapeutic peptides—A review

  2023cites this paper
• Drastic decline in vasoactive intestinal peptide expression in the suprachiasmatic nucleus in obese mice on a long-term high-fat diet.

  2023cites this paper
• Vazointestinal Peptid ve Naringeninin Rotenon Kaynaklı Deneysel Parkinson Hastalığı Modeli Üzerine Etkileri

  2023cites this paper
• Biosynthesis and function of VIP and oxytocin: mechanisms of C-terminal amidation, oxytocin secretion and transport.

  2023cites this paper
• Heme and Cu2+-induced vasoactive intestinal peptide (VIP) tyrosine nitration: A possible molecular mechanism for the attenuated anti-inflammatory effect of VIP in inflammatory diseases.

  2023cites this paper
• PACAP and VIP Neuropeptides’ and Receptors’ Effects on Appetite, Satiety and Metabolism

  2023cites this paper
• Gene Expression Analysis Links Autocrine Vasoactive Intestinal Peptide and ZEB1 in Gastrointestinal Cancers

  2023cites this paper
• The magic of small-molecule drugs during ex vivo expansion in adoptive cell therapy

  2023cites this paper
• Role of tear vasoactive intestinal peptide on dry eyes after laser keratorefractive surgery

  2023cites this paper
• The effect of acupuncture on pain and swelling of arthritis animal models: A systematic review and meta-analysis

  2023cites this paper
• Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice

  2023cites this paper
• CDS Cloning, Sequencing and Bioinformatic Analysis of Vasoactive Intestinal Peptide in Wahui Pigeon

  2022cites this paper
• Targeting vasoactive intestinal peptide-mediated signaling enhances response to immune checkpoint therapy in pancreatic ductal adenocarcinoma

  2022cites this paper
• NEUROGENIC INFLAMMATION AND PECULIARITIES OF THE AUTONOMIC NERVOUS SYSTEM IN PATIENTS WITH BRONCHIAL ASTHMA DEPENDING ON THE SEVERITY AND PHENOTYPE OF THE DISEASE

  2022cites this paper
• Therapeutic potential of vasoactive intestinal peptide and its receptor VPAC2 in type 2 diabetes

  2022cites this paper
• ENGINEERING OPTIMAL CAR T CELLS TO OVERCOME PANCREATIC TUMORS WITH SECRETED ANTAGONISTIC PEPTIDES

  2022cites this paper
• An Insight into Neuropeptides Inhibitors in the Biology of Colorectal Cancer: Opportunity and Translational Perspectives

  2022cites this paper
• Sympathetic activation leads to Schlemm's canal expansion via increasing vasoactive intestinal polypeptide secretion from trabecular meshwork.

  2022cites this paper
• Targeting VIP and PACAP Receptor Signaling: New Insights into Designing Drugs for the PACAP Subfamily of Receptors

  2022cites this paper
• The Role of Chicken Prolactin, Growth Hormone and Their Receptors in the Immune System

  2022cites this paper
• Donor plasmacytoid dendritic cells limit graft-versus-host disease through vasoactive intestinal polypeptide expression

  2022cites this paper
• The VIP/VPAC1R Pathway Regulates Energy and Glucose Homeostasis by Modulating GLP-1, Glucagon, Leptin and PYY Levels in Mice

  2022cites this paper
• An Experimental Model of Neuro–Immune Interactions in the Eye: Corneal Sensory Nerves and Resident Dendritic Cells

  2022cites this paper
• Mast cells in goldfish ( Carassius auratus ) gut: Immunohistochemical characterization

  2022cites this paper
• Cerebrospinal fluid and venous biomarkers of shunt-responsive idiopathic normal pressure hydrocephalus: a systematic review and meta-analysis

  2022cites this paper
• Tear film and ocular surface neuropeptides: Characteristics, synthesis, signaling and implications for ocular surface and systemic diseases.

  2022cites this paper
• Roles of gastrointestinal polypeptides in intestinal barrier regulation.

  2022cites this paper
• Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome

  2021cites this paper
• Pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide (Part 2): biology and clinical importance in central nervous system and inflammatory disorders.

  2021cites this paper
• 643 Vasoactive intestinal peptide as a novel immune checkpoint molecule in activated T cells

  2021cites this paper
• Tissue-Specific Molecular Markers and Heterogeneity in Type 2 Innate Lymphoid Cells

  2021cites this paper
• Pancreatic Vasoactive Intestinal Peptide Polypeptide-secreting Tumor With a Good Prognosis: a Case Report and Review of the Literature

  2021cites this paper
• Vasoactive intestinal peptide promotes host defense against enteric pathogens by modulating the recruitment of group 3 innate lymphoid cells

  2021cites this paper
• The Role of Neuropeptides in Pathogenesis of Dry Dye

  2021cites this paper
• Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP–VPAC2 signalling pathway

  2021cites this paper
• Neuropeptides of the human magnocellular hypothalamus.

  2021cites this paper
• Protocatechuic acid influences immune-metabolic changes in the adipose tissue of pregnant women with gestational diabetes mellitus.

  2021cites this paper
• Proteomic Analysis of Synovial Fibroblasts and Articular Chondrocytes Co-Cultures Reveals Valuable VIP-Modulated Inflammatory and Degradative Proteins in Osteoarthritis

  2021cites this paper
• Neuroendocrine Factors in Melanoma Pathogenesis

  2021cites this paper
• Current views on neuropeptides in atopic dermatitis

  2021cites this paper
• Type I Interferon Production of Plasmacytoid Dendritic Cells under Control

  2021cites this paper
• VIP modulates human macrophages phenotype via FPRL1 via activation of RhoA-GTPase and PLC pathways

  2021cites this paper
• The role of glia in Parkinson's disease: Emerging concepts and therapeutic applications.

  2020cites this paper
• Interplay between neutrophils and trophoblast cells conditions trophoblast function and triggers vascular transformation signals

  2020cites this paper
• VIP Promotes Recruitment of Tregs to the Uterine–Placental Interface During the Peri-Implantation Period to Sustain a Tolerogenic Microenvironment

  2020cites this paper
• Hydrophobically assembled nanoparticles

  2020cites this paper
• Implications of VIP and PACAP in Parkinson's disease: what do we know so far?

  2020cites this paper
• Co-hybridized composite nanovesicles for enhanced transdermal eugenol and cinnamaldehyde delivery and their potential efficacy in ulcerative colitis.

  2020cites this paper
• Triggering receptor expressed on myeloid cells-1 (TREM-1) as a therapeutic target in infectious and noninfectious disease: a critical review

  2020influential citation
• Lack of Mucosal Cholinergic Innervation Is Associated With Increased Risk of Enterocolitis in Hirschsprung’s Disease

  2020cites this paper
• Exosomes carry IL-10 and antigen/MHC II complexes to induce antigen-specific oral tolerance.

  2020cites this paper
• Panorama of mediators in postpancreatitis diabetes mellitus.

  2020cites this paper
• Function study of vasoactive intestinal peptide on chick embryonic bone development.

  2020cites this paper
• The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy

  2020cites this paper
• DIAGNOSTIC POTENTIAL OF SELECTED SALIVARY PROTEOMICS FOR AUTONOMIC NERVOUS SYSTEM ACTIVITY ASSESSMENT

  2020cites this paper
• Neuroprotective Immunity for Neurodegenerative and Neuroinfectious Diseases

  2020cites this paper
• Studies on the Optimization of Neuropeptides Detection in the Human Tear Film

  2020cites this paper
• Microbiota and gut neuropeptides: a dual action of antimicrobial activity and neuroimmune response

  2019cites this paper
• A Synthetic Agonist to Vasoactive Intestinal Peptide Receptor-2 Induces Regulatory T Cell Neuroprotective Activities in Models of Parkinson’s Disease

  2019cites this paper
• Vasoactive intestinal peptide ameliorates renal injury in a pristane-induced lupus mouse model by modulating Th17/Treg balance

  2019cites this paper
• Updating the picture of layer 2/3 VIP-expressing interneuron function in the mouse cerebral cortex.

  2019influential citation
• Neurotransmitters, neuropeptides and their receptors interact with immune response in healthy and psoriatic skin.

  2019cites this paper
• A Clinical Approach for the Use of VIP Axis in Inflammatory and Autoimmune Diseases

  2019influential citation